

# PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**PARKER ET AL.**

Examiner: L. R. Helms

Art Unit: 1642

Serial No.: **09/719,758**

Filed: January 4, 2002

Title: **MONOCLONAL ANTIBODIES  
DIRECTED AGAINST THE G3BP  
PROTEIN AND USES**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
First Class Mail in an envelope addressed to  
Commissioner for Patents, Washington, D.C.  
20231, on

Date of Deposit: 10/16/2003  
Signature: James Pearce, Sr.

## STATEMENT IN SUPPORT OF FILING AND SUBMISSION OF SEQUENCE LISTING

Commissioner for Patents  
Mail Stop PCT  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In connection with the Sequence Listing filed concurrently herewith, the undersigned states that

1. The submission does not contain new matter.
2. The content of the attached paper copy and the attached computer readable copy of the Sequence Listing are the same.

//

//

//

//

//


//

//

//

3. I declare under the laws of the United States of America that all statements of fact set forth above are true, and recognize that willfully false statements may jeopardize the validity of any patent that issues from this application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. B. German', written over a horizontal line.

Joel B. German, Reg. No. 48.676  
Attorney for Applicants

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3444  
Telefax (908) 231-2626  
Aventis Docket No. ST98017 US